Cytokine Release Syndrome and Immune-Related Pneumonitis Associated With Tumor Progression in a Pulmonary Pleomorphic Carcinoma Treated With Nivolumab Plus Ipilimumab Treatment: A Case Report.

Abstract

Effective control of severe immune-related adverse events, including cytokine release syndrome (CRS), is essential for the success of immunotherapy. We present a case of a granulocyte colony-stimulating factor-producing pleomorphic lung carcinoma treated with nivolumab plus ipilimumab which developed CRS and severe immune-related pneumonitis. The effect of immunotherapy was heterogeneous; gastric metastasis was eliminated, but the pulmonary lesion had primary resistance. Steroid and tocilizumab were successful in controlling CRS, but additional infliximab was necessary to control pneumonitis. To control immune-related adverse events, it is important to choose immunosuppressive agents to the specific target organ and inflammatory cells.

• Authors: Kei Kunimasa, Takako Inoue, Katsunori Matsueda, Takahisa Kawamura, Motohiro Tamiya, Kazumi Nishino, Toru Kumagai
• Journal: JTO clinical and research reports (JTO Clin Res Rep) Vol. 3 Issue 2 Pg. 100272 (Feb 2022) ISSN: 2666-3643 [Electronic] United States
• PMID: 35072122 (Publication Type: Case Reports)
• Copyright: © 2021 The Authors.